Cleared Traditional

K983107 - VFE

K983107 is an FDA 510(k) clearance for VFE, manufactured by Ramco Laboratories, Inc.. The device is a Class 2 Hematology device with product code GGP cleared through the Traditional 510(k) pathway after a 48-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 1998
Decision
48d
Days
Class 2
Risk

K983107 is an FDA 510(k) clearance for the VFE. Classified as Test, Qualitative And Quantitative Factor Deficiency (product code GGP), Class II - Special Controls.

Submitted by Ramco Laboratories, Inc. (Houston, US). The FDA issued a Cleared decision on October 22, 1998 after a review of 48 days - a notably fast clearance cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7290 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Ramco Laboratories, Inc. devices

FDA 510(k) Submission Details - K983107

510(k) Number K983107 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 04, 1998
Decision Date October 22, 1998
Days to Decision 48 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
65d faster than avg
Panel avg: 113d · This submission: 48d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

GGP Device Classification - Class 2, Special Controls

Product Code GGP Test, Qualitative And Quantitative Factor Deficiency
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7290
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - GGP Test, Qualitative And Quantitative Factor Deficiency

All 155
Devices cleared under the same product code (GGP) and FDA review panel - the closest regulatory comparables to K983107.
IL TEST VON WILLEBRAND FACTOR
K992704 · Instrumentation Laboratory CO · Nov 1999
BIOCLOT APC SENSITIVITY
K983898 · Biopool Intl., Inc. · Jan 1999
REAADS MONOCLONAL FREE PROTEIN S ANTIGEN TEST KIT
K983914 · Corgenix, Inc. · Dec 1998
COAMATIC PLASMIN INHIBITOR
K981817 · Instrumentation Laboratory CO · Sep 1998
IL TEST PLASMIN INHIBITOR
K981696 · Instrumentation Laboratory CO · Aug 1998
SHIELD ACTIVATED FACTOR XII (ELISA) ASSAY
K980885 · Shield Diagnostics, Ltd. · Aug 1998